The estimated Net Worth of Todd Michael Wood is at least $2.11 Million dollars as of 12 June 2023. Mr. Wood owns over 350 units of Obalon Therapeutics Inc stock worth over $788,777 and over the last 7 years he sold OBLN stock worth over $1,320,203. In addition, he makes $0 as Vice President - Global Sales at Obalon Therapeutics Inc.
Todd has made over 23 trades of the Obalon Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 350 units of OBLN stock worth $998 on 12 June 2023.
The largest trade he's ever made was selling 10,000 units of Obalon Therapeutics Inc stock on 25 May 2021 worth over $400,000. On average, Todd trades about 1,585 units every 31 days since 2018. As of 12 June 2023 he still owns at least 284,757 units of Obalon Therapeutics Inc stock.
You can see the complete history of Mr. Wood stock trades at the bottom of the page.
Todd Wood is Vice President - Global Sales of the Company. Mr. Wood was most recently Vice President Sales, U.S. Dermatology for Allergan where he created and implemented an expansion plan for product launch. Prior to that, he was Vice President Sales, U.S. Eye Care for Allergan where he developed the strategic sales infrastructure for the entire U.S. Eye Care sales organization.
Todd's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, , ALPHARETTA, GA, 30005.
Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma..., and David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.
Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.
Obalon Therapeutics Inc executives and other stock owners filed with the SEC include: